Omega Therapeutics Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Omega Therapeutics Inc 's ROA in the third quarter of 2024?
Omega Therapeutics Inc recorded a cumulative net loss of $-73 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -104.22%.

However, within the Healthcare sector 560 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2024 quarter, so far to 4140, from total ROA ranking in the second quarter of 2024 at 4146.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter
Y / Y Total Assets Change	-58.94 %	-53.21 %	-50.4 %	-32.77 %	-35.15 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-73	-79	-92	-97	-108
Return On Assets (TTM)	-104.22 %	-91.65 %	-88.98 %	-79.05 %	-79.98 %
OMGA's Total Ranking	# 4140	# 4146	# 4257	# 4975	# 4578
Total Assets (TTM) in million	44	62	77	97	108
Seq. Total Assets Change	-28.29 %	-19.4 %	-20.88 %	-10.22 %	-18.27 %
Seq. Net Income Change	-	-	-	-	-

OMGA's 5 Years Annual ROA >> Back to OMGA Management Effectiveness >> Compare OMGA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 80
Sector	# 561
Overall	# 4065

Return On Assets Statistics
High	Average	Low
-36.39 %	-48.39 %	-64.81 %
(Mar 31 2022)		(Mar 31 2023)

Financial Statements
Omega Therapeutics Inc 's Assets	$ 44 million	OMGA's Balance sheet
Omega Therapeutics Inc 's Income	$ -16 million	Quarterly OMGA's Income Statement
OMGA's Income by Division		See OMGA's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY	FY
Y / Y Total Assets Change	-31.93 %	-38.81 %	-	-	-
Total Assets in million	97	143	233	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-97	-103	-68	0	0
Annual Return On Assets	-100.24 %	-71.93 %	-29.26 %	-	-

OMGA's 5 Years Annual ROA >> Back to OMGA Management Effectiveness >> Compare OMGA ROA to its Competitors

More Return On Assets Ratios
OMGA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
OMGA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for OMGA's Competitors
Subscribers only: Roa for Omega Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for OMGA's Customers

You may also want to know
OMGA's Roi	OMGA's Inventory Turnover Ratio	OMGA's Growth Rates	OMGA's Dividend Comparisons
	OMGA's Profitability Ratios	OMGA's Asset Turnover Ratio	OMGA's Dividend Growth
OMGA's Roe	OMGA's Valuation Ratios	OMGA's Financial Strength Ratios	OMGA's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.